OakChart

Opus Genetics Inc

IRDHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 1:06 PM ET

4.40+0.17 (4.02%)
2026-11-11 19:07 CET
Market cap
351.92 USD m
Revenue, TTM
7.91 USD m
Net income, TTM
-136.65 USD m
Free cash flow, TTM
-48.73 USD m
EPS diluted, TTM
-1.59
P/E
-
Compare

Price

IRD against its 20, 50 and 200-day averages
2050200beatmiss
3.004.005.006.007.0027.2M54.3MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26IRDclose 4.4020-day 3.8950-day 4.51200-day 4.254.4052w high

37.8% under the 52-week high of 7.07 on 9 Sep 2026. 52-week low 1.70 on 18 Nov 2025. Last 15 sessions, 36.8% high to low

Profile

IRD
52-week range, 50% of the way up
1.707.07

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Durham, NC.

IndexRUT
Employees28
IPONov 30, 2004
Beta0.78
ATR, 14d0.31
Rel volume0.41
Short float16.10%
Insider own18.89%
Inst own68.19%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap366.06M
Enterprise Value312.97M
Income-136.65M
Sales7.91M
Book/sh0.40
Cash/sh1.07
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees28
IPONov 30, 2004

Ratios

P/E-
Forward P/E-
PEG-
P/S46.28
P/B10.97
P/C4.11
P/FCF-
EV/EBITDA-
EV/Sales39.57
Quick Ratio9.65
Current Ratio9.65
Debt/Eq0.93
LT Debt/Eq0.93
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.59
EPS next Y-0.74
EPS next Q-0.09
EPS this Y-51.94%
EPS next Y38.76%
EPS next 5Y30.59%
EPS past 3/5Y- 31.49%
Sales past 3/5Y-29.11% -
EPS Y/Y TTM10.87%
Sales Y/Y TTM-45.92%
EPS Q/Q-84.74%
Sales Q/Q-63.07%
EarningsNov 10 BMO
EPS/Sales Surpr.-215.93% -26.49%

Ownership

Insider Own18.89%
Insider Trans-13.26%
Inst Own68.19%
Inst Trans13.94%
ROA-207.97%
ROE-615.57%
ROIC-183.89%
Gross Margin99.22%
Oper. Margin-777.66%
Profit Margin-1726.70%
SMA2013.08%
SMA50-2.40%
SMA2003.54%
Trades-

Technical

Shs Outstand95.80M
Shs Float67.48M
Short Float16.10%
Short Ratio4.34
Short Interest10.86M
52W High7.07 -37.77%
52W Low1.70 158.82%
Volatility7.54% 7.95%
ATR (14)0.31
RSI (14)57.41
Beta0.78
Rel Volume0.41
Avg Volume2.50M
Volume586,903

Performance

Perf Week3.04%
Perf Month3.77%
Perf Quarter18.28%
Perf Half Y-12.52%
Perf YTD118.91%
Perf Year123.35%
Perf 3Y55.48%
Perf 5Y11.11%
Perf 10Y-94.54%
Recom1.00
Target Price13.94
Prev Close4.23
Price4.40
Change %4.02%

Analyst ratings

latest 10 of 14
DateActionAnalystRating changeTargetImplied
Jul 29, 2026InitiatedTTD CowenBuy
Jun 23, 2026InitiatedRRBC Capital MktsOutperform$10+127.3%
Jun 04, 2026InitiatedGGuggenheimBuy$16+263.6%
May 21, 2026InitiatedLLeerink PartnersOutperform$10+127.3%
Apr 28, 2026InitiatedCCitizensMkt Perform$12+172.7%
Mar 30, 2026InitiatedCCantor FitzgeraldOverweight$15+240.9%
Mar 16, 2026InitiatedOOppenheimerOutperform$10+127.3%
Jan 20, 2026InitiatedBBTIG ResearchBuy$7+59.1%
Dec 10, 2025InitiatedRB. Riley SecuritiesBuy$9+104.5%
Nov 25, 2025InitiatedPPiper SandlerOverweight$7+59.1%

Peers

Mkt cap
TickerCompanyMkt cap
MGTXMeiraGTx Holdings plc924.55M
FDMT4D Molecular Therapeutics Inc689.44M
LENZLENZ Therapeutics Inc132.59M
EYPTEyePoint Inc31.60M
OCULOcular Therapeutix Inc1.46B
OCSOculis Holding AG483.98M
KODKodiak Sciences Inc6.98B
BLTEBelite Bio Inc ADR6.31B
ALDXAldeyra Therapeutics Inc38.12M
KALAKala Bio Inc3.27M

Insider trading

latest 14 of 42
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Magrath GeorgeChief Executive OfficerNov 03 '26Sale3.9028,258110,1842,010,636Nov 05 04:04 PM
Magrath GeorgeOfficerNov 03 '26Proposed Sale3.9028,258110,184Nov 03 03:50 PM
SCHACHLE JOSEPH KChief Operating OfficerOct 23 '26Sale3.564,76716,994286,673Oct 27 04:47 PM
YERXA BENJAMIN RPresidentOct 23 '26Sale3.5433,189117,365670,917Oct 27 04:41 PM
Gagnon Robert E.Chief Financial OfficerOct 23 '26Sale3.5514,00049,650542,375Oct 27 04:29 PM
Magrath GeorgeChief Executive OfficerOct 23 '26Sale3.589,59134,3842,038,894Oct 27 04:20 PM
YERXA BENJAMIN ROfficerOct 23 '26Proposed Sale3.5433,189117,365Oct 23 04:57 PM
Gagnon Robert E.OfficerOct 23 '26Proposed Sale4.0114,00056,140Oct 23 04:04 PM
Magrath GeorgeOfficerOct 23 '26Proposed Sale3.599,59134,384Oct 23 02:48 PM
Foundation Fighting BlindnessDirectorSep 30 '26Sale4.96556,0002,755,9813,236,171Oct 02 07:47 PM
Magrath GeorgeChief Executive OfficerSep 09 '26Option Exercise1.15392,157450,9812,124,026Sep 11 04:09 PM
Gallagher CamDirectorSep 08 '26Option Exercise1.15784,314901,9612,800,111Sep 08 04:05 PM
Gagnon Robert E.Chief Financial OfficerSep 03 '26Sale4.5428,000127,212556,375Sep 08 04:05 PM
Gagnon Robert E.OfficerSep 03 '26Proposed Sale4.4528,000124,600Sep 03 04:11 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
VFMOVanguard U.S. Momentum Factor ETFAUM: 1.82B
IWCiShares Micro-Cap ETFAUM: 1.22B
SURISimplify Propel Opportunities ETFAUM: 74.30M
GSSCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFAUM: 1.06B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B

News

latest 14 of 206
  • Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update (GlobeNewswire)
  • Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal Diseases (GlobeNewswire) -6.21%
  • Opus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference (GlobeNewswire) +6.22%
  • Opus Genetics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
  • Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations (GlobeNewswire)
  • Loading…
  • Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness (GlobeNewswire)
  • FDA approves Viatris' Ryzumvi for adult presbyopia (Pharmaceutical Business Review)
  • Opus Genetics Secures FDA Approval For Eye Drops Set To Receive Milestone Payment (Stocktwits) -5.19%
  • Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia (GlobeNewswire)
  • Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026 (GlobeNewswire)
  • Opus Genetics to Present at the Chardan Annual Healthcare Conference (GlobeNewswire) -8.62%
  • FDA Decision Watch: RHHBY, VTRS And IRD Face Key October Drug Rulings As MRK Withdraws Application (Stocktwits)
  • IRD Stock Hits Over 5-Year Highs Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial (Stocktwits) +32.03%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.460-0.146-0.4601.141.5518
2026Q22026-08-06-0.140-0.157-0.1390.762.6318
2026Q12026-05-12-0.750-0.134-0.7542.162.9312
2025Q42026-03-10-0.190-0.112-0.2363.873.1412
2025Q32025-11-12-0.250-0.130-0.2473.083.077
2025Q22025-08-13-0.120-0.205-0.1172.884.054
2025Q12025-05-15-0.240-0.250-0.2424.373.103
2024Q42025-03-31-1.270-0.245-1.1134.303.402
2024Q32024-11-12-0.290-0.238-0.2883.872.284
2024Q22024-08-13-0.300-0.255-0.3011.112.454
2024Q12024-05-10-0.290-0.110-0.2901.715.344
2023Q42024-03-08-0.210-0.053-0.2091.695.364
2023Q32023-11-130.250-0.2220.24811.943.035
2023Q22023-08-11-0.240-0.226-0.2373.672.435
2023Q12023-05-15-0.280-0.154-0.2771.752.955
2022Q42023-03-301.5801.3151.58039.8529.454

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-21.120-23.400-20.9530.000.00
2020FY-5.280-1.445-5.2820.001.20
2021FY-3.820-3.005-3.8170.590.50
2022FY0.8700.6680.86939.8529.44
2023FY-0.460-0.298-0.46319.0522.68
2024FY-2.150-1.120-2.15410.9910.10
2025FY-0.800-0.667-0.80014.2013.48
2026FY--1.216--12.08
2027FY--0.744--10.57
2028FY--0.268--36.35
2029FY--0.118--96.26
2030FY-0.398--226.49

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-1017557.740.0024.70
2026Q4S2026-10-2117227.540.0022.60
2026Q4S2026-10-2017427.540.0022.60
2026Q4S2026-10-1617576.950.0022.60
2026Q4S2026-09-0817576.860.0021.12
2026Q4S2026-09-0716567.290.0021.12
2026Q4S2026-09-0316567.290.0021.12
2026Q4S2026-08-2717567.130.0021.12
2026Q4S2026-08-2017557.230.0021.12
2026Q4S2026-08-1918557.380.0021.12
2026Q4S2026-08-0918557.380.0021.12
2026Q4S2026-08-0718567.380.0021.12
2026Q4S2026-08-0618366.950.0021.12
2026Q4S2026-07-2817017.630.0018.65

Estimate history

EPS, annual-44.16-20.953-8.674-5.282-3.8170.869-0.463-2.154-0.797-1.5862
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.288-1.113-0.242-0.117-0.247-0.236-0.754-0.139-0.457
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00000.58939.8519.04910.99214.1967.91
Period201720182019202020212022202320242025TTM
Sales, quarterly3.8674.3024.372.8823.0793.8652.1570.7551.137
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.6610.7820.71310.88218.84620.86123.97731.57569.89595.8
Period201720182019202020212022202320242025MRQ
Shares, quarterly26.19831.57545.48459.90864.54469.89571.40282.64895.8
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue7.9114.2010.9919.0539.850.590.000.000.00
Cost of Goods Sold Incl. D&A0.060.050.010.010.000.000.010.000.05
Gross Profit7.8514.1410.9819.0439.850.58-0.01-0.00-0.05
Selling, General and Administrative Excl. Other69.4052.7445.0629.6121.6223.299.464.1920.49
Research and Development46.7130.8126.8517.6514.3615.176.652.3713.11
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-61.54-38.60-34.07-10.5618.23-22.70-9.47-4.19-20.54
Interest Expense1.441.47-0.000.010.006.851.410.00
Unusual Expense78.5111.5227.94-0.050.0033.838.320.50-5.55
Net Income Before Taxes-136.65-49.59-57.53-9.9718.20-56.69-24.62-6.17-14.37
Income Taxes0.000.000.000.010.320.000.000.000.00
Consolidated Net Income-136.65-49.59-57.53-9.9917.89-56.69-24.62-6.17-14.37
Net Income From Continuing Operations-136.65-49.59-57.53-9.9917.89-56.69-24.62-6.17-14.37
Net Income-136.65-49.59-57.53-9.9917.89-56.69-24.62-6.17-14.37
EPS (Recurring)-0.87-0.67-1.42-0.460.87-2.22-4.03-8.18-26.61
EPS (Basic, Before Extraordinaries)-1.53-0.80-2.15-0.460.90-3.82-5.28-8.67-20.95
EPS (Diluted)-1.59-0.80-2.15-0.460.87-3.82-5.28-8.67-20.95
EBITDA-61.48-38.55-34.06-10.5618.23-22.70-9.46-4.19-20.49
Non-Operating Income (Expense)4.851.994.480.54-0.01-0.160.01-0.070.62
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.243.403.362.771.431.911.510.311.23
Price To Earnings Ratio---2.29-----
Price To Sales Ratio62.288.812.893.411.8294.06---
Gross Margin99.2299.6399.9199.9799.9999.32---
Operating Margin-777.66-271.90-309.99-55.4545.74-3,854.84---
Net Margin-1,726.70-349.33-523.40-52.4244.89-9,625.30---
Shares Outstanding95.8069.8931.5723.9820.8618.8510.880.710.78
Market Capitalization351.92351.9237.5768.1473.4564.5346.037.6834.90

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue1.140.762.163.873.082.884.374.30
Cost of Goods Sold Incl. D&A0.020.010.010.010.010.010.010.01
Gross Profit1.110.742.143.853.072.874.364.29
Selling, General and Administrative Excl. Other20.3617.2216.5115.3011.3811.7714.2914.32
Research and Development14.4911.2110.5810.436.416.027.957.03
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-19.25-16.48-14.36-11.45-8.31-8.91-9.93-10.03
Interest Expense0.100.630.650.060.07-1.37-
Unusual Expense28.61-7.1751.365.719.53-0.92-2.8027.93
Net Income Before Taxes-46.49-8.10-65.53-16.52-17.45-7.42-8.19-35.13
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-46.49-8.10-65.53-16.52-17.45-7.42-8.19-35.13
Net Income From Continuing Operations-46.49-8.10-65.53-16.52-17.45-7.42-8.19-35.13
Net Income-46.49-8.10-65.53-16.52-17.45-7.42-8.19-35.13
EPS (Recurring)-0.26-0.18-0.34-0.18-0.15-0.13-0.30-0.49
EPS (Basic, Before Extraordinaries)-0.46-0.08-0.75-0.24-0.25-0.12-0.24-1.11
EPS (Diluted)-0.46-0.14-0.75-0.24-0.25-0.12-0.24-1.11
EBITDA-19.23-16.47-14.35-11.44-8.30-8.89-9.92-10.02
Non-Operating Income (Expense)1.461.840.840.700.450.570.302.82
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.591.411.460.770.820.900.910.80
Price To Sales Ratio62.2846.4532.999.907.963.872.443.42
Gross Margin98.0798.1599.4099.6699.5899.5199.7099.77
Operating Margin-1,692.79-2,182.78-665.92-296.33-269.93-309.02-227.21-233.12
Net Margin-4,089.27-1,072.58-3,038.25-427.50-566.87-257.46-187.51-816.71
Shares Outstanding95.8082.6571.4069.8964.5459.9145.4831.57
Market Capitalization351.92339.35323.73138.6298.8556.2143.4637.57

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments45.0930.3250.5242.6824.7516.401.5414.7326.83
Short Term Receivables3.175.772.334.850.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.790.521.101.451.311.270.151.171.30
Total Current Assets50.0436.6153.9548.9926.0717.671.6915.9028.14
Net Property, Plant & Equipment0.200.250.000.010.010.010.020.110.12
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.000.000.00
Deferred Tax Assets0.030.030.000.64-----
Other Assets0.000.000.000.000.000.000.080.030.03
Total Assets50.2736.8953.9549.6326.0817.681.7816.0428.29
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.540.005.670.000.00
Accounts Payable3.293.152.151.071.580.000.000.550.00
Income Tax Payable--0.000.32-----
Other Current Liabilities4.498.151.891.371.733.193.682.613.23
Total Current Liabilities7.7811.294.042.753.853.199.343.153.23
Long Term Debt1.1318.840.000.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.0027.960.000.000.00
Deferred Tax Liabilities0.030.030.000.64-----
Other Liabilities25.980.000.000.000.000.000.002.338.29
Total Liabilities34.9230.164.043.393.8531.159.345.4811.52
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity15.356.7249.9146.2422.22-13.47-7.5610.5616.77
Total Shareholders Equity15.356.7249.9146.2422.22-13.47-7.5610.5616.77
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity15.356.7249.9146.2422.22-13.47-7.5610.5616.77
Total Liabilities & Stockholders Equity50.2736.8953.9549.6326.0817.681.7816.0428.29
Book Value Per Share0.220.212.082.221.18-1.24-10.6013.5125.37
Tangible Book Value Per Share0.220.212.082.221.18-1.24-10.6013.5125.37
Full-Time Employees28181499551017
Price to Book Ratio10.540.911.356.183.160.930.773.303.80
Return on Assets-113.79-126.67-19.2847.26-259.11-160.65-69.21-64.82-102.55
Return on Equity-449.36-203.19-20.7752.26-1,295.10--410.87-105.14-149.55
Return on Invested Capital-300.97-225.02-20.0138.69-255.12---136.03-150.84
Quick Ratio6.433.2413.3517.796.765.550.185.048.70
Current Ratio6.433.2413.3517.796.765.550.185.048.70

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-136.65-49.59-57.53-9.9917.89-56.69-24.62-6.17-14.37
Depreciation0.060.050.010.010.000.000.010.000.05
Other Funds (Non Cash)85.1616.4428.864.791.9837.1416.672.22-4.77
Funds from Operations-51.43-33.10-28.67-5.1919.87-19.55-7.94-3.95-19.09
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital2.88-2.153.094.08-5.550.181.150.360.15
Cash from Operating Activities-48.55-35.25-25.58-1.1114.31-19.37-6.80-3.59-18.94
Capital Expenditures-0.190.000.000.000.000.000.00-0.03-0.04
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments0.000.000.000.000.000.000.000.0011.95
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.0011.95
Other Uses0.000.000.000.000.00-0.10-1.480.000.00
Other Sources0.000.001.210.000.000.002.010.000.00
Cash from Investing Activities-0.190.001.210.000.00-0.100.54-0.0311.91
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock73.1149.024.198.984.3227.070.060.006.87
Repurchase of Common Pref Stock-0.15-0.15-0.080.000.000.000.000.000.00
Sale of Common Pref Stock73.2649.174.268.984.3227.070.060.006.87
Proceedsfrom Stock Options25.863.504.268.954.3026.980.000.006.87
Issuance or Reduction of Debt, Net33.891.000.000.00-0.540.542.194.700.00
Change in Long Term Debt33.891.000.000.000.000.000.000.000.00
Issuance of Long Term Debt35.001.000.000.000.000.000.000.000.00
Reduction of Long Term Debt-1.110.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.0018.880.000.00
Other Financing Activities Uses0.000.000.000.000.000.00-2.270.000.00
Cash from Financing Activities106.9950.024.198.983.7927.6121.124.706.87
Net Change in Cash58.2614.77-20.187.8718.108.1314.861.09-0.15
Free Cash Flow-48.73-35.25-25.58-1.1114.31-19.37-6.80-3.62-18.98
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow----5.08----
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments88.9788.8159.9645.0930.8232.43
Short Term Receivables1.631.462.713.174.284.58
Inventories0.000.000.000.000.000.00
Other Current Assets4.252.433.931.790.811.43
Total Current Assets94.8692.7066.6050.0435.9138.44
Net Property, Plant & Equipment0.340.170.190.200.210.23
Total Investments and Advances0.100.100.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Deferred Tax Assets---0.03--
Other Assets0.000.000.000.000.000.00
Total Assets95.3092.9766.7950.2736.1238.66
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable3.731.884.423.292.401.47
Other Current Liabilities6.115.724.924.4926.6918.73
Total Current Liabilities9.837.619.347.7829.0920.19
Long Term Debt35.8836.2025.931.131.071.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.03--
Other Liabilities11.1562.1577.3525.980.000.00
Total Liabilities56.86105.95112.6234.9230.1621.19
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity38.43-12.99-45.8415.355.9717.47
Total Shareholders Equity38.43-12.99-45.8415.355.9717.47
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity38.43-12.99-45.8415.355.9717.47
Total Liabilities & Stockholders Equity95.3092.9766.7950.2736.1238.66
Book Value Per Share0.40-0.16-0.640.220.090.29
Tangible Book Value Per Share0.40-0.16-0.640.220.090.29
Full-Time Employees---28--
Price to Book Ratio10.54-6.4020.7221.745.668.45
Return on Assets-207.97-163.50-186.04-113.79-178.28-139.58
Return on Equity-615.57-4,796.52--449.36-338.75-200.57
Return on Invested Capital-62.57-34.88--100.28-248.10-40.17
Quick Ratio9.6512.197.136.431.231.90
Current Ratio9.6512.197.136.431.231.90

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-46.49-8.10-65.53-16.52-17.45-7.42
Depreciation0.020.010.010.010.010.01
Other Funds (Non Cash)30.52-4.8652.906.6010.41-0.06
Funds from Operations-15.95-12.95-12.62-9.91-7.03-7.46
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.920.99-0.100.070.88-2.81
Cash from Operating Activities-14.04-11.95-12.73-9.83-6.16-10.27
Capital Expenditures-0.190.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.190.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock14.397.0227.5924.114.54-0.09
Repurchase of Common Pref Stock0.000.36-0.39-0.120.000.00
Sale of Common Pref Stock14.396.6627.9924.234.54-0.09
Proceedsfrom Stock Options0.004.5127.25-5.904.52-0.09
Issuance or Reduction of Debt, Net0.0033.890.000.000.001.00
Change in Long Term Debt0.0033.890.000.000.001.00
Issuance of Long Term Debt0.0035.000.000.000.001.00
Reduction of Long Term Debt0.00-1.110.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities14.3940.9027.5924.114.540.91
Net Change in Cash0.1628.9514.8714.28-1.61-9.36
Free Cash Flow-14.22-11.95-12.73-9.83-6.16-10.27

Revenue breakdown

Total Pharmaceutical Preparations revenue2024: 10.99M 2025: 14.20M
United States2024: 10.99M 2025: 14.20M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3016.10%10.9M67.5M2.49M
2026-10-1519.77%13.3M67.5M2.42M
2026-09-3019.34%13.0M67.3M2.27M
2026-09-1518.85%12.6M66.7M2.18M
2026-08-3116.12%10.9M67.7M961.19K
2026-08-1416.61%11.2M67.7M952.23K
2026-07-3116.02%10.8M67.7M990.97K
2026-07-1515.29%10.3M67.2M995.20K
2026-06-3012.29%8.2M66.9M959.62K
2026-06-158.57%5.7M66.9M816.54K
2026-05-295.94%3.9M66.0M898.87K
2026-05-154.71%3.1M66.0M918.23K
2026-04-303.69%2.0M54.2M971.93K
2026-04-153.28%1.8M55.1M972.70K
2026-03-313.45%1.8M53.6M940.55K
2026-03-133.76%2.0M53.6M866.46K
2026-02-272.14%1.1M51.9M767.76K
2026-02-131.81%0.9M51.9M686.14K
2026-01-301.28%0.7M51.9M584.58K
2026-01-151.77%1.0M54.2M498.74K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.501.203.201.7511.3483630.000.945-0.0110.001
call5.000.000.100.091.0503,8741.000.250-0.0130.002
call7.500.000.050.052.9219390.000.170-0.0260.002
call10.000.000.150.253.0811850.000.066-0.0150.001
put2.500.000.050.050.00059.000.00-0.102-0.0830.001
put5.000.002.001.515.98250.000.00-0.748-0.0120.002
put7.501.005.503.8311.7080.000.00-0.917-0.0120.001
put10.003.508.005.8012.7420.000.00-0.934-0.0130.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-11-054Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-11-03144Filing for proposed sale of securities under Rule 144.SEC
2026-10-27SCHEDULE 13GSEC
2026-10-274Statement of changes in beneficial ownership of securities2026-10-23SEC
2026-10-274Statement of changes in beneficial ownership of securities2026-10-23SEC
2026-10-274Statement of changes in beneficial ownership of securities2026-10-23SEC
2026-10-274Statement of changes in beneficial ownership of securities2026-10-23SEC
2026-10-23144Filing for proposed sale of securities under Rule 144.SEC
2026-10-23144Filing for proposed sale of securities under Rule 144.SEC
2026-10-23144Filing for proposed sale of securities under Rule 144.SEC
2026-10-218-KCurrent report2026-10-19SEC
2026-10-158-KCurrent report2026-10-14SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-118-KCurrent report2026-09-11SEC
2026-09-098-KCurrent report2026-09-09SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-03144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14EFFECTEffectiveness filing by commission orderSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13CORRESPSEC
2026-08-12UPLOADUpload SubmissionSEC
2026-08-07S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1100110.18K1
2026-1000218.39K4
2026-09002.88M2
2026-080000
2026-070086.59K4
2026-060000
2026-05007.40M1
2026-0400201.64K6
2026-0300180.67K4
2026-020000
2026-010000
2025-12323.69K28.60M1
2025-110000

Institutional holders

Manager% owned
Nantahala Capital Management, LLC7.42%
Caligan Partners LP7.36%
ADAGE CAPITAL PARTNERS GP, L.L.C.7.30%
BIOS Capital Management, LP4.46%
BlackRock, Inc.3.77%
BALYASNY ASSET MANAGEMENT L.P.3.74%
VANGUARD CAPITAL MANAGEMENT LLC3.58%
Boxer Capital Management, LLC3.41%
Trails Edge Capital Partners, LP3.32%
MILLENNIUM MANAGEMENT LLC2.79%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.71%
iShares Russell 2000 ETF1.63%
VANGUARD EXTENDED MARKET INDEX FUND0.79%
Fidelity Small Cap Index Fund0.71%
iShares Russell 2000 Growth ETF0.61%
VANGUARD RUSSELL 2000 INDEX FUND0.37%
Fidelity Extended Market Index Fund0.32%
iShares Micro-Cap ETF0.22%
Schwab Small-Cap Index Fund0.16%
Master Small Cap Index Series0.12%

OakChart. IRD. Cached 15 minutes.